U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H24N2O8.H2O
Molecular Weight 462.4498
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXYCYCLINE

SMILES

O.[H][C@@]12[C@@H](C)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@]4(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]4([H])[C@H]2O

InChI

InChIKey=XQTWDDCIUJNLTR-CVHRZJFOSA-N
InChI=1S/C22H24N2O8.H2O/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29;/h4-7,10,14-15,17,25,27-29,32H,1-3H3,(H2,23,31);1H2/t7-,10+,14+,15-,17-,22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H24N2O8
Molecular Weight 444.4346
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Doxycycline is an antibacterial drug synthetically derived from oxytetracycline and used to treat a wide variety of bacterial infections, including those that cause acne. Doxycycline is used for bacterial pneumonia, acne, chlamydia infections, early Lyme disease, cholera, and syphilis. It is also useful for the treatment of malaria when used with quinine and for the prevention of malaria. Common side effects include diarrhea, nausea, vomiting, a red rash, and an increased risk of a sunburn. If used during pregnancy or in young children may result in permanent problems with the teeth including changes in their color. Its use during breastfeeding is probably safe. Like other tetracycline antibiotics, Doxycycline is protein synthesis inhibitors, inhibiting the binding of aminoacyl-tRNA to the mRNA-ribosome complex by binding to the 30S ribosomal subunit in the mRNA translation complex.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

1967
Curative
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

1967
Primary
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

1967
Curative
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

1967
Curative
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

1967
Curative
Periostat

Approved Use

Uses temporarily relieves the minor aches and pains of muscles and joints associated with simple backache arthritis strains bruises sprains

Launch Date

1967
Curative
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

1967
Curative
VIBRAMYCIN

Approved Use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis (formerly Pasteurella pestis). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis). Cholera caused by Vibrio cholerae (formerly Vibrio comma). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum. Yaws caused by Treponema pertenue. Listeriosis due to Listeria monocytogenes. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (< 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.

Launch Date

1967
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.17 μg/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DOXYCYCLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
32 μg × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DOXYCYCLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.5 h
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DOXYCYCLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.86
unhealthy, 23.9
n = 190
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 23.9
Sex: M+F
Population Size: 190
Sources: Page: p.86
Disc. AE: Vomiting, Dysphagia...
AEs leading to
discontinuation/dose reduction:
Vomiting (0.5%)
Dysphagia (0.5%)
Hypersensitivity (0.5%)
Sources: Page: p.86
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.86
unhealthy, 24.1
n = 188
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 24.1
Sex: M+F
Population Size: 188
Sources: Page: p.86
Disc. AE: Headache, Hypersensitivity...
AEs leading to
discontinuation/dose reduction:
Headache (0.5%)
Hypersensitivity (0.5%)
Sources: Page: p.86
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Disc. AE: Dyspepsia, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Dyspepsia (0.45%)
Abdominal pain (0.45%)
Nausea (0.45%)
Vomiting (0.45%)
Chest pain (0.45%)
Dyspnea (0.45%)
Sources: Page: p.114
40 mg 1 times / day steady, oral
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adults
n = 84
Health Status: unhealthy
Condition: Papulopustular Rosacea
Age Group: adults
Population Size: 84
Sources:
Other AEs: Chest pain, Abortion spontaneous...
Other AEs:
Chest pain (serious, 1 patient)
Abortion spontaneous (serious, 1 patient)
Nausea (below serious, 3 patients)
Sinusitis (below serious, 3 patients)
Sources:
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Other AEs: Pulmonary embolism, Umbilical hernia...
Other AEs:
Pulmonary embolism (serious, 1 patient)
Umbilical hernia (serious, 1 patient)
Vomiting (serious, 1 patient)
Constipation (below serious, 1 patient)
Fatigue (below serious, 1 patient)
Gout (below serious, 1 patient)
Headaches (below serious, 2 patients)
Prostatitis (below serious, 1 patient)
Urinary retention (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dysphagia 0.5%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.86
unhealthy, 23.9
n = 190
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 23.9
Sex: M+F
Population Size: 190
Sources: Page: p.86
Hypersensitivity 0.5%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.86
unhealthy, 23.9
n = 190
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 23.9
Sex: M+F
Population Size: 190
Sources: Page: p.86
Vomiting 0.5%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.86
unhealthy, 23.9
n = 190
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 23.9
Sex: M+F
Population Size: 190
Sources: Page: p.86
Headache 0.5%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.86
unhealthy, 24.1
n = 188
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 24.1
Sex: M+F
Population Size: 188
Sources: Page: p.86
Hypersensitivity 0.5%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.86
unhealthy, 24.1
n = 188
Health Status: unhealthy
Condition: Urogenital Chlamydia trachomatis infection
Age Group: 24.1
Sex: M+F
Population Size: 188
Sources: Page: p.86
Abdominal pain 0.45%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Chest pain 0.45%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Dyspepsia 0.45%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Dyspnea 0.45%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Nausea 0.45%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Vomiting 0.45%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.114
unhealthy, 24.7
n = 223
Health Status: unhealthy
Condition: Chlamydia trachomatis endocervical infection
Age Group: 24.7
Sex: F
Population Size: 223
Sources: Page: p.114
Nausea below serious, 3 patients
40 mg 1 times / day steady, oral
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adults
n = 84
Health Status: unhealthy
Condition: Papulopustular Rosacea
Age Group: adults
Population Size: 84
Sources:
Sinusitis below serious, 3 patients
40 mg 1 times / day steady, oral
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adults
n = 84
Health Status: unhealthy
Condition: Papulopustular Rosacea
Age Group: adults
Population Size: 84
Sources:
Abortion spontaneous serious, 1 patient
40 mg 1 times / day steady, oral
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adults
n = 84
Health Status: unhealthy
Condition: Papulopustular Rosacea
Age Group: adults
Population Size: 84
Sources:
Chest pain serious, 1 patient
40 mg 1 times / day steady, oral
Dose: 40 mg, 1 times / day
Route: oral
Route: steady
Dose: 40 mg, 1 times / day
Sources:
unhealthy, adults
n = 84
Health Status: unhealthy
Condition: Papulopustular Rosacea
Age Group: adults
Population Size: 84
Sources:
Constipation below serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Fatigue below serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Gout below serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Prostatitis below serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Urinary retention below serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Headaches below serious, 2 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Pulmonary embolism serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Umbilical hernia serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Vomiting serious, 1 patient
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 15
Health Status: unhealthy
Condition: Proliferative Diabetic Retinopathy
Population Size: 15
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
PubMed

PubMed

TitleDatePubMed
Evaluation of a new antibacterial agent. Doxycycline monohydrate and doxycycline hyclate (Vibramycin).
1969 Jul 28
[Leukocytoclastic vasculitis due to drug allergy presenting as generalized pustular exanthema].
1981 Sep
Screening for new compounds with antiherpes activity.
1984 Oct
Tetracycline-induced renal hypophosphatemia in a patient with a syndrome of inappropriate secretion of antidiuretic hormone.
1988
Anosmia after doxycycline use.
1990 Apr 16
In vitro and in vivo effects of doxycycline on Toxoplasma gondii.
1990 May
[In vitro activity of sparfloxacin against mycoplasmas].
1992 May
In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi.
1994 Oct
Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii.
1996
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.
1996 Dec
Ataxia following docetaxel infusion.
1997 Aug
Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.
1997 May
Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.
1998 Dec
Neurotic effects of doxycycline sclerotherapy.
1998 Mar
Functional and histochemical analysis of MDR3 P-glycoprotein in a tetracycline-controlled gene expression system.
2000 Dec 29
[Clinical use of tetracyclines in the treatment of periodontal diseases].
2000 May-Jun
In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum.
2002 Feb
Antiprotozoals effective in vitro against the scuticociliate fish pathogen Philasterides dicentrarchi.
2002 Jun 3
Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.
2002 Oct
Doxycycline induced intracranial hypertension.
2003 Mar 22
Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production.
2003 Nov
Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry.
2005 Apr
Effect of doxycycline on sulfur mustard-induced respiratory lesions in guinea pigs.
2005 Jul
Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial.
2005 Jun 18-24
Doxycycline may reduce the incidence of aneurysms in haemodialysis vascular accesses.
2005 May
[Skin signs associated with epidermal growth factor inhibitors].
2006 Mar
Doxycycline-induced amnesia: a case report.
2007 Jan
Sulfated glucosamine inhibits MMP-2 and MMP-9 expressions in human fibrosarcoma cells.
2007 Jul 15
Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases.
2007 Mar 15
Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome.
2008 Jan
Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice.
2008 Mar
De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model.
2009 Dec 1
A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy.
2009 Jul
Doxycycline-induced pseudotumor cerebri.
2009 Mar
Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension.
2009 May
Doxycycline-induced dizziness in dental patient. Case report.
2010 Aug-Sep
Original quinazoline derivatives displaying antiplasmodial properties.
2010 Feb
Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea.
2010 Jun
Integrin-linked kinase is involved in cocaine sensitization by regulating PSD-95 and synapsin I expression and GluR1 Ser845 phosphorylation.
2010 Mar
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.
2013 Sep 5
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

Periostat (Doxycycline hyclate) 20 mg twice daily as an adjunct following scaling and root planing may be administered for up to 9 TM months. Safety beyond 12 months and efficacy beyond 9 months have not been established. Periostat should be administered at least one hour prior to morning and evening meals
Route of Administration: Oral
PC3 cells were incubated with LPS (0.5 μg/mL) for 24 h in the presence or absence of doxycycline (5 μg/mL). The effects of LPS and doxycycline on the expressions of MMP-2, MMP-8, MMP-9, MMP-10, NF-κB/p65, IκB-α, p-IκB-α, IKK-β were examined by Western blotting and immunohistochemistry in PC3 cells. LPS increased expression and activity of MMP-9 and expression of MMP-8, MMP-10, NF-κB /p65, p-IκB-α, IKK-β and doxycycline down-regulated its effects with the exception of MMP-10 expression.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:01:14 GMT 2023
Edited
by admin
on Fri Dec 15 15:01:14 GMT 2023
Record UNII
N12000U13O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOXYCYCLINE
MART.   MI   ORANGE BOOK   USAN   USP   VANDF  
USAN  
Official Name English
DOXYCYCLINE [MI]
Common Name English
SUPRACYCLIN
Brand Name English
DOXYCYCLINE [USAN]
Common Name English
DOXYCYCLINE [ORANGE BOOK]
Common Name English
ORACEA
Brand Name English
DOXYCYCLINE MONOHYDRATE [VANDF]
Common Name English
DOXYCYCLINE MONOHYDRATE [USP-RS]
Common Name English
2-NAPHTHACENECARBOXAMIDE, 4-(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,5,10,12,12A-PENTAHYDROXY-6-METHYL-1,11-DIOXO-, (4S-(4.ALPHA.,4A.ALPHA.,5.ALPHA.,5A.ALPHA.6.ALPHA.,12A.ALPHA.))-, MONOHYDRATE
Common Name English
DOXYCYCLINE [VANDF]
Common Name English
DOXYCYCLINE MONOHYDRATE [MART.]
Common Name English
DOXIROBE
Brand Name English
DOXYCYCLINE MONOHYDRATE [EP MONOGRAPH]
Common Name English
DOXYCYCLINE [USP MONOGRAPH]
Common Name English
DOXYLIN
Brand Name English
DOXYCYCLINE MONOHYDRATE [EP IMPURITY]
Common Name English
DOXYCYCLINE (EMA EPAR: VETERINARY)
Common Name English
MONODOX
Brand Name English
GS-3065
Code English
XYROSA
Brand Name English
DOXYCYCLINE MONOHYDRATE
EP   MART.   VANDF   WHO-DD  
Common Name English
DOXYCHEL
Brand Name English
Doxycycline monohydrate [WHO-DD]
Common Name English
4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrate
Common Name English
Classification Tree Code System Code
WHO-VATC QA01AB22
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
WHO-ATC J01AA02
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.2
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
NDF-RT N0000007948
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.5.3.2
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
WHO-ATC A01AB22
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
NCI_THESAURUS C1595
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
NDF-RT N0000007948
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
EMA VETERINARY ASSESSMENT REPORTS DOXIROBE
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
WHO-VATC QJ01AA02
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.5.3.1
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
LIVERTOX NBK548353
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
NDF-RT N0000175882
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
Code System Code Type Description
IUPHAR
6464
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
DRUG BANK
DB00254
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
MESH
D004318
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
DAILYMED
N12000U13O
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
ChEMBL
CHEMBL1433
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
EPA CompTox
DTXSID401045241
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
MERCK INDEX
m4758
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY Merck Index
RXCUI
203122
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
RXCUI
3640
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
ALTERNATIVE
CAS
17086-28-1
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
RS_ITEM_NUM
1225984
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
FDA UNII
N12000U13O
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
EVMPD
SUB01832MIG
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
NCI_THESAURUS
C457
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
CHEBI
60648
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
LACTMED
Doxycycline
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
WIKIPEDIA
DOXYCYCLINE
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
SMS_ID
100000092800
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
CHEBI
50845
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
DRUG CENTRAL
961
Created by admin on Fri Dec 15 15:01:14 GMT 2023 , Edited by admin on Fri Dec 15 15:01:14 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TARGET ORGANISM->INHIBITOR
ANHYDROUS->SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
BINDER->LIGAND
BINDING
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC POPULATION: END-STAGE RENAL DISEASE

MIC BIOLOGICAL PATHOGEN: NOCARDIAE AND OTHER AEROBIC ACTNOMYCES spp.

SUSCEPTIBILITY: RESISTANT

MIC BIOLOGICAL PATHOGEN: ACINETOBACTER spp., ENTEROBACTERIACEAE, FRANCISELLA TULARENSIS, VIBRIO CHOLREA, YERSINIA PESTIS

SUSCEPTIBILITY: RESISTANT

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: ACINETOBACTER spp., ENTEROBACTERIACEAE, FRANCISELLA TULARENSIS, VIBRIO CHOLREA, YERSINIA PESTIS

MIC BIOLOGICAL SUSCEPTIBILITY: INTERMEDIATE

PATHOGEN: ACINETOBACTER spp., ENTEROBACTERIACEAE, FRANCISELLA TULARENSIS, VIBRIO CHOLREA, YERSINIA PESTIS

MIC BIOLOGICAL SUSCEPTIBILITY: INTERMEDIATE

PATHOGEN: NOCARDIAE AND OTHER AEROBIC ACTNOMYCES spp.

MIC BIOLOGICAL PATHOGEN: S. PNEUMONIAE

SUSCEPTIBILITY: INTERMEDIATE

Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

FORMULATION: IMMEDIATE RELEASE

MIC BIOLOGICAL SUSCEPTIBILITY: RESISTANT

PATHOGEN: S. PNEUMONIAE

Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

FORMULATION: DELAYED-RELEASE TABLET

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: NOCARDIAE AND OTHER AEROBIC ACTNOMYCES spp., BRUCELLA spp., BACILLUS ANTRHACIS

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: S. PNEUMONIAE